Lunit "To Present Two Collaborative AI Biomarker Studies at SITC 2026"
Lunit, a medical artificial intelligence (AI) company, used AI to analyze cancer tissue and identify clues that distinguish patients’ responses to immunotherapy. The findings showed that the location of immune cells within a tumor is more closely associated with treatment response than their number.
According to Lunit on Nov. 5, the company plans to present two collaborative studies using its AI biomarker platform, Lunit SCOPE, at the Society for Immunotherapy of Cancer (SITC 2026), taking place in Phoenix, U.S., from Nov. 4 to 8 (local time).
An analysis conducted with CellCarta of tissue samples from patients with muscle-invasive bladder cancer before and after immunotherapy found that patients who responded to treatment had greater immune cell infiltration, with cancer-attacking T cells located closer to the tumor. In patients who did not respond, most T cells had impaired function and were located far from the tumor.
With Labcorp, Lunit analyzed tissue samples from 339 patients with ovarian cancer. Among patients with homologous recombination deficiency (HRD), a defect in DNA damage repair, the density of proliferating cells was about 1.5 times that of patients without HRD. Their tumor mutational burden (TMB) was also twice as high. The score from an AI model that predicts HRD status based solely on tissue images showed a significant correlation with genomic test results.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
“Reading complex relationships among cells all at once is an area where AI can excel,” said Lunit CEO Seo Beomseok. “We will further develop Lunit SCOPE into an essential platform for next-generation biomarker analysis.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.